Summary Increased cancer risk has been associated with functional polymorphisms that occur within the genes coding for the Nacetyltransferase enzymes NAT1 and NAT2. We detected two NAT1 polymorphisms in colorectal cancer patients by heteroduplex analysis. DNA sequencing revealed the wild-type sequence (NAT1*4) and two single base substitutions at adjacent positions 999 bp (C to T, NAT1*14) and 1000 bp (G to A, NAT1*15) of the gene, changing Arg187 to a stop codon and Arg187 to Gin respectively. NAT1 alleles NAT1*4 (0.98) and NAT1*15 (0.02) were present at a similar frequency in patients with colorectal cancer (n = 260) and in a Scottish control group (n = 323). The third allele, NAT1*14, was present only in the colorectal cancer group at a frequency of 0.006. NAT1 genotype NAT1*4/ NAT1*15 was significantly less frequent in individuals that had a slow NAT2 genotype. This was observed in both cancer and control groups and suggests that this association was unrelated to cancer risk. We conclude that polymorphisms within the coding region of the NAT1 gene are infrequent and do not appear to have an independent association with colorectal cancer risk. However, the relationship between NAT1 and NAT2 polymorphisms appears non-random, suggesting a linkage between these enzymes.
The N-acetyl transferases (NAT1 and NAT2, also known as AACl and AAC2) are xenobiotic enzymes that metabolize inhaled or ingested carcinogenic compounds, including arylamine and heterocyclic amine compounds present in cigarette smoke (Vineis, 1994) and in cooked food (Sugimura et al, 1994) . Both NATI and NAT2 genes are known to reside on chromosome 8p (Blum et al, 1990; Franke et al, 1994) . Polymorphic forms of NAT genes have the potential to affect an individual's response to carcinogens thereby influencing cancer risk. Polymorphisms of NAT2 that result in slow acetylation of metabolites have been associated with bladder cancer (Risch et al, 1995) and, conversely, fast acetylators may be more common in colorectal cancer and some types of breast cancer (Lang et al, 1986; Agundez et al, 1995) . However these associations are weak and are not supported by all studies (Bell et al, 1995a; Hubbard et al, 1997) .
A potentially confounding factor in these assessments is the contribution of NATI, a closely related enzyme that shares some substrate specificity with NAT2 (Hein et al, 1992) , which is expressed at higher levels than NAT2 in colonic epithelial cells (Turesky et al, 1991) . Recent studies have shown that NATI is also polymorphic and 15 variants have been detected in animal and human gene sequences Weber and Vatsis, 1993; Grant et al, 1997) . One variant, the NAT1*10 allele, is more frequent in patients with bladder and colon cancer (Bell et al, 1995a) . The NAT1 * 10 allele contains a single base substitution in the polyadenylation signal in the 3' untranslated region of the gene which results in increased NATI enzyme activity (Bell et al, 1995b) and raises the possibility that the NATI enzyme may function as a carcinogen activator in some individuals. We examined the NATI gene coding sequence and present data on two polymorphisms within the coding sequence of the NATI gene, and a simple method for the detection of these polymorphisms in DNA samples.
MATERIALS AND METHODS Study cases
Peripheral blood and colorectal cancer tissue was collected from a consecutive series of operable colorectal cancer patients after surgery in three local hospitals between 1988 and 1993 (Edinburgh Royal Infirmary, Edinburgh, UK; Western General Hospital, Edinburgh, UK; St Johns Hospital, Livingstone, UK). Age at diagnosis ranged between 20 and 95 years and cases were equally distributed for gender. Cancer diagnosis was confirmed histopathologically and were classified according to Dukes' stages (A, B, C) and according to position of cancer in the colon as either right (caecum, ascending and transverse) or left (sigmoid, descending and rectum) sides. A random control cohort was provided by Dr Peng Lee Yap, Scottish National Blood Transfusion Service, Edinburgh, UK. Samples of peripheral blood were obtained from healthy individuals attending routine occupational screening, with approximately equal male to female ratios and distributed over the age range 18-65 years. Both cancer and control groups were from the same Caucasian population base. Collection of blood from cancer patients has been given local ethical approval. DNA was extracted from peripheral blood lymphocytes using standard methods (Cantlay et al, 1995) .
The polymorphic status of the N-acetyltransferase 2 gene in these cancer and control groups was determined previously (Hubbard et al, 1997 
NAT1
The NATI gene was examined for polymorphism using primers designed from the published human gene sequence (Blum et al, 1990 
Heteroduplex analysis
Polymorphic alleles were identified by heteroduplex analysis.
Duplexes were formed by denaturation of 20 gl of PCR product at 95°C for 3 min, followed by cooling to 37°C over 30 min. Samples were separated by shape and size on x 1 MDE polyacrylamide gels (Pharmacia-Hoeffer, UK), in x 0.6 Tris borate buffer (NBL Gene Sciences, UK) containing 18% (w/v) urea, at 600 V for 16 h. DNA present in gels was silver stained using the following protocol: 10% ethanol for 10 min, 1% nitric acid for 10 min, distilled water for 5 min, 0.24% (w/v) silver nitrate for 20 min, distilled water rinse for 10 s. Silver staining was developed in two changes of 230 mm sodium carbonate and 0.05% formaldehyde (37%) and fixed in 0.1 M citric acid.
DNA sequencing Samples with variant and invariant banding patterns were DNA sequenced using the Sequenase protocol (Amersham Life Sciences, UK). NATl-specific sequences were PCR amplified as above, except for substitution of the antisense primer for an identical biotinylated primer. Amplified DNA was purified using the Wizard DNA clean-up system (Promega, UK) and denatured using streptavidin-coated superparamagnetic beads (Dynabeads, Dynal, Norway), both according to manufacturers' instructions. The sense strand was sequenced according to the Sequenase protocol using 0.5 pmol of primer P2 and 5 ,uCi of [a-35S]dATP. Samples were denatured at 950C for 3 min, then electrophoresed on 6% denaturing polyacrylamide gels at 65 W for 2 h. Gels were fixed in 10% methanol, 10% acetic acid and then dried under vacuum for 2 h. Dried gels were exposed to X-Omat radiographic film overnight and developed automatically in a X2 Hyperprocessor (Amersham, UK). The DNA sequence was determined manually.
Data analysis
Allele frequencies for each group were calculated and genotype distribution for cancers and controls were tested for goodness of fit with the Hardy-Weinberg equilibrium. Any deviations from this equilibrium were calculated using a chi-squared test. Genotype distributions of the colon cancer and control groups were compared using the chi-squared test incorporating Yates continuity correction, and P-values less than 0.05 were considered to be significant.
RESULTS
Detection and identification of NAT1 coding sequence polymorphisms Using NATI specific primers, a 225-bp DNA fragment was amplified from 260 colon cancer patient DNAs, and heteroduplex analysis produced a common single band pattern (allele NAT1 *4) and a variant pattern of two or three bands on silver stained polyacrylamide gels (Figure 1 ). DNA sequencing of the variant samples identified two separate base changes, G to A at position 1000 bp (allele NATl * 15) or C to T at position 999 bp (allele NAT1 * 14) of the NAT1 gene (Figure 2 ). These base changes result in an amino acid substitution Arg'87-Gln ( NATi * 15) and a stop British Journal of Cancer (1998) 77(6), [913] [914] [915] [916] NAT1 polymorphisms in colorectal cancer 915 , one of which is thought to affect enzyme activity (Bell et al, 1995b are infrequent, and allow analysis of multiple xenobiotic enzyme polymorphisms. However, infrequent alleles are likely to have only a small influence on overall risk. The substitution of the hydrophilic amino acid glycine for arginine (allele NAT1*15) at codon 187 may affect enzyme activity and specificity, as this domain is thought to be critical for determining substrate specificity (Dupret et al, 1994) . The introduction of a stop codon (allele NATI* 14) at codon'57, results in the loss of 104 amino acids from the C-terminus of NAT1. Although the putative active site remains with the truncated protein (residues 47-l11), the C-terminus amino acids (residues 211-250) play an important role in enzyme stability, and residues 112-210 determine specificity (Dupret et al, 1994) . Therefore, this polymorphism is likely to severely impair or abrogate enzyme function. However, there may only be small differences in enzyme activity between genotypes NATI*4/*4, NATI*4/*14 and NATI*4/*15.
This has yet to be demonstrated biochemically. It is interesting to note that allele NAT1* 14 was found only in colon cancer patients. The NAT1 genotype NATI*4/NAT1*15 was less frequent than expected, if random distribution is assumed, in individuals with a slow NAT2 genotype in both the control and the cancer groups. This may represent genetic linkage between NATI and NAT2, which are closely related and have overlapping substrate specificity (Turesky et al, 1991) . This linkage may confound studies of NAT1 and NAT2 polymorphism with disease susceptibility.
Polymorphisms within the coding region of the NAT1 gene are infrequent and do not appear to be independently associated with colorectal cancer risk. However, these alleles are likely to affect enzyme activity and may be in linkage with particular alleles of the NAT2 gene.
